Randomised control trial of oxygen assist module in preterm infants on high-flow nasal cannula support

Abstract

ObjectiveTo evaluate the efficacy of automatic oxygen control (A-FiO2) in reducing the extremes of oxygen saturations (SpO2<80% and SpO2>98%) in preterm infants on high-flow nasal cannula (HFNC) respiratory support using Vapotherm Precision Flow.DesignA parallel-arm randomised controlled trial.SettingA level-III neonatal intensive care unit.PatientsPreterm infants born <33 (23+0 to 32+6) weeks receiving HFNC as respiratory support.InterventionsA-FiO2versus manual (M-FiO2) oxygen control during the full course of HFNC support.OutcomesThe primary outcome of this study is percentage of time spent in extreme oxygen saturations (<80% and >98%) in preterm infants when receiving HFNC as respiratory support. Secondary outcomes were time with SpO2between 90% and 95% plus time >95% without supplemental oxygen.Results60 infants were randomised equally to either A-FiO2or M-FiO2arm. Their baseline characteristics were comparable. They spent a median of 5.3 (IQR: 2.0–8.4) and 6.5 (IQR: 2.9–13.7) days in the study, A-FiO2and M-FiO2, respectively. The percentage of time spent in SpO2<80% (median of 0.4% (0.1%–0.8%) vs 1.6% (0.6%–2.6%), p=0.002) and >98% (median 0.2% (0.1%–0.9%) vs 1.9% (0.7%–4%), p<0.001) were significantly lower in A-FiO2compared with M-FiO2. The difference in median percentage of time in target range between the two arms was 26% (81% (74%–93%) in A-FiO2vs 55% (48%–72%) in M-FiO2).ConclusionA-FiO2was associated with statistically significant reduction in the percentage of time spent in extremes of saturation when compared with M-FiO2in preterm infants receiving HFNC.Trial registration numberNCT04687618.